Sutro Biopharma, Inc. (FRA:S090)

Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of EUR 107.20 million. The enterprise value is -19.00 million.

Market Cap	107.20M
Enterprise Value	-19.00M

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	8.52M
Shares Outstanding	n/a
Shares Change (YoY)	+17.26%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	1.69%
Owned by Institutions (%)	39.53%
Float	6.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.19
PB Ratio	-1.44
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.10
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.10

Financial Position

The company has a current ratio of 2.53

Current Ratio	2.53
Quick Ratio	2.39
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-3.77

Financial Efficiency

Return on equity (ROE) is -1,810.01% and return on invested capital (ROIC) is -256.77%.

Return on Equity (ROE)	-1,810.01%
Return on Assets (ROA)	-25.80%
Return on Invested Capital (ROIC)	-256.77%
Return on Capital Employed (ROCE)	-99.12%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	505,854
Profits Per Employee	-1.04M
Employee Count	178
Asset Turnover	0.32
Inventory Turnover	n/a

Taxes

In the past 12 months, Sutro Biopharma has paid 2.00 million in taxes.

Income Tax	2.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.17% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.17%
50-Day Moving Average	8.79
200-Day Moving Average	7.57
Relative Strength Index (RSI)	60.30
Average Volume (20 Days)	8

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.76

Income Statement

In the last 12 months, Sutro Biopharma had revenue of EUR 90.04 million and -184.75 million in losses. Loss per share was -22.05.

Revenue	90.04M
Gross Profit	123.05M
Operating Income	-116.38M
Pretax Income	-182.75M
Net Income	-184.75M
EBITDA	-109.93M
EBIT	-116.38M
Loss Per Share	-22.05

Balance Sheet

The company has 142.84 million in cash and 15.05 million in debt, with a net cash position of 127.79 million.

Cash & Cash Equivalents	142.84M
Total Debt	15.05M
Net Cash	127.79M
Net Cash Per Share	n/a
Equity (Book Value)	-74.38M
Book Value Per Share	-8.74
Working Capital	93.94M

Cash Flow

In the last 12 months, operating cash flow was -189.67 million and capital expenditures -2.20 million, giving a free cash flow of -191.86 million.

Operating Cash Flow	-189.67M
Capital Expenditures	-2.20M
Free Cash Flow	-191.86M
FCF Per Share	n/a

Margins

Gross margin is 136.66%, with operating and profit margins of -129.26% and -205.18%.

Gross Margin	136.66%
Operating Margin	-129.26%
Pretax Margin	-202.96%
Profit Margin	-205.18%
EBITDA Margin	-122.09%
EBIT Margin	-129.26%
FCF Margin	n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.26%
Shareholder Yield	-17.26%
Earnings Yield	-172.34%
FCF Yield	-178.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 3, 2025. It was a reverse split with a ratio of 0.1.

Last Split Date	Dec 3, 2025
Split Type	Reverse
Split Ratio	0.1

Scores

Sutro Biopharma has an Altman Z-Score of -6.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.97
Piotroski F-Score	1